You seem to be using a wider screen, would you like to enable a wider viewing experience on this page?
NESTE Q3’24: No quick fixes
Neste: a new CEO is in place, but the short-term turmoil continues. The key uncertainty factors are the gross margin in Renewable Products and the current oversupply in the market. Valuation of the share is mixed and multiples very high with this year's weak performance - still long term potential. Analyst Petri Gostowski summarizes.
Content:
00:00 Intro
00:21 Q3
01:11 How can Neste improve the situation?
02:21 Oversupply in the market
02:59 Other key factors
04:07 Valuation
05:54 Recommendation
Herantis Pharma as an Investment | Life Science Night Dec. 2, 2024
Aiforia as an Investment | Life Science Night Dec. 2, 2024
Faron Pharmaceuticals as an Investment | Life Science Night Dec. 2, 2024
Life Science Companies as Investments | Life Science Night Dec. 2, 2024
Life Science Night | December 2, 2024
View all videos